2026-08-27

NEUCA with an over 45% growth rate of operating profit in the wholesale distribution of medicines segment in the second quarter of 2026

NEUCA with an over 45% growth rate of operating profit in the wholesale distribution of medicines segment in the second quarter of 2026
  • In the second quarter of 2026, the value of the pharmacy wholesale market amounted to PLN 12.8 bn, growing year on year by 6.3%1 (cumulatively: PLN 25.8 bn with a growth rate of 4.1%). The decisive influence on this growth rate came from the change in the product sales structure and the launch of new pharmaceuticals2.
  • In the April-June period this year, NEUCA Group generated almost PLN 3.6 bn in sales revenues which were 9.3% higher than in the same period a year earlier. After six months, the Group’s sales exceeded PLN 7.1 bn (as against PLN 6.6 bn in the first half of 2025). Cumulatively, shares in the pharmacy wholesale market amounted to 28.8%3 (+0.1 pp year on year), and in the independent pharmacies segment: 37.7%4 (+0.3 pp year on year). 
  • The value of the Net Promoter Score referral rate in the second quarter of 2026 is 67 points5. In the customer satisfaction ranking, NEUCA invariably takes the highest places in each of the surveyed categories6.  
  • At the end of the first half of this year, over 2,000 independent pharmacies took part in the Świat Zdrowia and Partner partnership programmes (2,020 pharmacies, i.e. 82 more than at the end of June 2025). 
  • The second quarter of 2026 confirmed the upward trend in financial performance observed in the January-March period this year. The EBITDA profit of NEUCA Group was almost 33% higher and amounted to nearly PLN 100 m (PLN 98.8 m, i.e. +32.3% year on year), while net profit attributable to shareholders of the Parent doubled to PLN 40.8 m (+105.6% year on year). 

– The hero of the second quarter was the wholesale distribution of medicines segment, with an over 45% growth rate of operating profit year on year. Growth in sales revenues of 8.0% in the second quarter of this year exceeded the value growth rate of the market, mainly thanks to growth in shares in the chain pharmacies segment and their stabilisation in the independent pharmacies segment. At the same time, the nominal gross margin grew, while average profitability was maintained which was achieved despite an unfavourable product structure of the market (a lower share of pharmaceuticals with a contractual price vs an official price). All these factors were complemented by an improvement in cost efficiency, achieved despite the increase in fuel prices – says Grzegorz Dzik, President of the Board of Directors of NEUCA S.A.

In the second quarter, NEUCA Group effectively pursued its strategic objectives. It invariably takes the highest place in each of the surveyed categories of the customer satisfaction ranking. This level of trust in the Group translates into strong interest and a stable number of participants in our partnership programmes. As a consequence, NEUCA keeps high market shares.

For more information, please see the press release available at the following link: LINK.

 

 


1 Value of the market for wholesale distribution to pharmacies according to IQVIA
2 PHARMASCOPE (IQVIA) – in-house research by ODOKA​​​​​​​
3 Percentage share of NEUCA in the market of wholesale distribution of medicines to pharmacies according to IQVIA​​​​​​​
4 Estimated percentage share of NEUCA in the value of the market of wholesale distribution of medicines to independent pharmacies based on IQVIA​​​​​​​
5 Pharmacist Satisfaction Barometer, the Company’s in-house study.​​​​​​​
6 IQVIA